The latest price target for Tenet Healthcare (NYSE:THC) was reported by Cantor Fitzgerald on February 13, 2025. The analyst firm set a price target for $177.00 expecting THC to rise to within 12 months (a possible 40.45% upside). 50 analyst firms have reported ratings in the last year.

The latest analyst rating for Tenet Healthcare (NYSE:THC) was provided by Cantor Fitzgerald, and Tenet Healthcare reiterated their overweight rating.

The last upgrade for Tenet Healthcare Corp happened on March 27, 2024 when Wolfe Research raised their price target to $122. Wolfe Research previously had a peer perform for Tenet Healthcare Corp.

The last downgrade for Tenet Healthcare Corp happened on December 16, 2024 when Goldman Sachs changed their price target from $196 to $140 for Tenet Healthcare Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tenet Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tenet Healthcare was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.

While ratings are subjective and will change, the latest Tenet Healthcare (THC) rating was a reiterated with a price target of $177.00 to $177.00. The current price Tenet Healthcare (THC) is trading at is $126.02, which is out of the analyst’s predicted range.